Skip to main content

Advertisement

SpringerLink
Log in

Significance of HER2 and Ki-67 in Preneoplastic Lesions and Carcinoma of Gallbladder

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

HER2 is an oncoprotein which is overexpressed in several cancers including breast and stomach. Several studies have shown that HER2 is overexpressed in gallbladder cancer and in precancerous lesions. The present study was undertaken to assess pattern and level of expression of HER2 in metaplasia, dysplasia, and different stages of gallbladder carcinoma, which would determine its suitability as a prognostic biomarker in neoplastic transformation of gallbladder epithelium. The study was also aimed at to find the significance of Ki-67 index in these lesions.

Methods and Materials

One hundred and twenty-eight patients who underwent cholecystectomy comprised the study group. Among them, 108 (84.4%) specimens showing metaplasia, dysplasia, and carcinoma on routine histopathology were considered as cases and 20 (15.6%) specimens of chronic cholecystitis having non-metaplastic mucosa were considered as control. Immunohistochemistry (IHC) was performed for HER2 and Ki-67. For HER2 interpretation ASCO/CAP guideline for breast cancer was followed. Chi-square test was used to find out the significance of HER2 expression in dysplasia/metaplasia/carcinoma. The ANOVA and Tukey-Kramer Multiple Comparisons Test were used for determining the association of Ki-67 with malignant transformation.

Results and Conclusions

Overexpression of HER2 was observed in 48% (n = 12) of adenocarcinomas, 58% (n = 7) of high-grade dysplasia, 47% (n = 8) of low-grade dysplasia, and 74% (n = 25) of intestinal metaplasia. Ki-67 index increases in a non-linear fashion as the precursor lesions progress toward malignancy. In the future, these markers might be used as a prognostic biomarker for gallbladder carcinoma and its precursor lesions and it might become a valid indication for targeted therapies for gallbladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol. 2003;4(3):167–76.

    Article  Google Scholar 

  2. Are C, Ahmad H, Ravipati A, Croo D, Clarey D, Smith L, et al. Global epidemiological trends and variations in the burden of gallbladder cancer. J Surg Oncol. 2017;115(5):580–90. https://doi.org/10.1002/jso.24546.

    Article  PubMed  Google Scholar 

  3. Jönsson PE, Pettersson BA. Carcinoma of the gallbladder—a natural history type of study. J Surg Oncol. 1982;21(4):215–8.

    Article  Google Scholar 

  4. Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver. 2012;6(2):172–87. https://doi.org/10.5009/gnl.2012.6.2.172.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51(6):349–64.

    Article  CAS  Google Scholar 

  6. Roa I, de Toro G, Schalper K, de Aretxabala X, Churi C, Javle M. Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer. Gastrointest Cancer Res. 2014;7(2):42–8.

    PubMed  PubMed Central  Google Scholar 

  7. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–50. https://doi.org/10.1093/jnci/djp082.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523–9. https://doi.org/10.1093/annonc/mdn169.

    Article  CAS  PubMed  Google Scholar 

  9. Takei K, Watanabe H, Itoi T, Saito T. p53 and Ki-67 immunoreactivity and nuclear morphometry of ‘carcinoma-in-adenoma’ and adenoma of the gall-bladder. Pathol Int. 1996;46(6):426–35.

    Article  CAS  Google Scholar 

  10. Toledo C, Matus CE, Barraza X, et al. Expression of HER2 and bradykinin B1 receptors in precursor lesions of gallbladder carcinoma. World J Gastroenterol: WJG. 2012;18(11):1208–15. https://doi.org/10.3748/wjg.v18.i11.1208.

    Article  CAS  PubMed  Google Scholar 

  11. Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010;10:631. https://doi.org/10.1186/1471-2407-10-631.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Neyaz A, Husain N, Gupta S, et al. Investigation of targetable predictive and prognostic markers in gallbladder carcinoma. J Gastrointest Oncol. 2018;9(1):111–25. https://doi.org/10.21037/jgo.2017.10.02.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Rakha EA, Starczynski J, Lee AH, Ellis IO. The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice. Histopathology. 2014;64(5):609–15. https://doi.org/10.1111/his.12357.

    Article  PubMed  Google Scholar 

  14. Hart J, Shani M, Modan B. Epidemiological aspects of gallbladder and biliary tract neoplasm. Am J Public Health. 1972;62(1):36–9.

    Article  CAS  Google Scholar 

  15. Zatonski WA, Lowenfels AB, Boyle P, Maisonneuve P, Bueno de Mesquita HB, Ghadirian P, et al. Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer. J Natl Cancer Inst. 1997;89(15):1132–8.

    Article  CAS  Google Scholar 

  16. Puhalla H, Wrba F, Kandioler D, Lehnert M, Huynh A, Gruenberger T, et al. Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer. Anticancer Res. 2007;27(3B):1679–84.

    CAS  PubMed  Google Scholar 

  17. Chaube A, Tewari M, Garbyal RS, Singh U, Shukla HS. Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients manuscript id:8962091628764582. BMC Cancer. 2006;6:126.

    Article  Google Scholar 

  18. Ashai F, Ashraf A, Rashid A, Banday BM, Bhalla S, Dhawan S. Expression of Her2/neu receptor in carcinoma gallbladder correlates significantly with advanced tumor stage. Int J Hepatobiliary Pancreat Dis. 2015;5:86–91.

    Article  Google Scholar 

  19. Kawamoto M, Horibe T, Kohno M, Kawakami K. HER2-targeted hybrid peptide that blocks HER2 tyrosine kinase disintegrates cancer cell membrane and inhibits tumor growth in vivo. Mol Cancer Ther. 2013;12(4):384–93. https://doi.org/10.1158/1535-7163.MCT-12-0357.

    Article  CAS  PubMed  Google Scholar 

  20. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992;70(6):1493–7.

    Article  CAS  Google Scholar 

  21. Pujani M, Makker I, Makker A, Jetley S, Goel MM, Jetley S. Expression of human epidermal growth factor receptor (her 2/neu) and proliferative marker Ki-67: association with clinicopathological parameters in gallbladder carcinoma. Asian Pac J Cancer Prev. 2016;17(8):3903–9.

    PubMed  Google Scholar 

  22. Xuan YH, Choi YL, Shin YK, Kook MC, Chae SW, Park SM, et al. An immunohistochemical study of the expression of cell-cycle-regulated proteins p53, cyclin D1, RB, p27, Ki67 and MSH2 in gallbladder carcinoma and its precursor lesions. Histol Histopathol. 2005;20(1):59–66. https://doi.org/10.14670/HH-20.59.

    Article  CAS  PubMed  Google Scholar 

  23. Stancu M, Căruntu ID, Sajin M, Giuşcă S, Bădescu A, Dobrescu G. Immunohistochemical markers in the study of gallbladder premalignant lesions and cancer. Rev Med Chir Soc Med Nat Iasi. 2007;111(3):734–43.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, ESI PGIMSR, Manicktala Kolkata, 54 Bagmari Road, Kolkata, West Bengal, 7000054, India

    Sutapa Halder, Sayan Kundu, Jayati Chakraborty & Sudipta Chakrabarti

Authors
  1. Sutapa Halder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sayan Kundu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jayati Chakraborty
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sudipta Chakrabarti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sayan Kundu.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Halder, S., Kundu, S., Chakraborty, J. et al. Significance of HER2 and Ki-67 in Preneoplastic Lesions and Carcinoma of Gallbladder. J Gastrointest Canc 50, 848–854 (2019). https://doi.org/10.1007/s12029-018-0162-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-018-0162-8

Keywords

Search

Navigation